Connect Biopharma Holdings Ltd
NASDAQ:CNTB

Watchlist Manager
Connect Biopharma Holdings Ltd Logo
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Watchlist
Price: 0.9509 USD -4.19% Market Closed
Market Cap: 52.5m USD
Have any thoughts about
Connect Biopharma Holdings Ltd?
Write Note

Connect Biopharma Holdings Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Connect Biopharma Holdings Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Total Liabilities & Equity
ÂĄ125.9m
CAGR 3-Years
-51%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities & Equity
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Liabilities & Equity
ÂĄ20.3B
CAGR 3-Years
7%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities & Equity
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities & Equity
ÂĄ54.8B
CAGR 3-Years
26%
CAGR 5-Years
38%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities & Equity
ÂĄ6.9B
CAGR 3-Years
14%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Connect Biopharma Holdings Ltd
Glance View

Market Cap
52.5m USD
Industry
Biotechnology

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.

CNTB Intrinsic Value
0.3275 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Connect Biopharma Holdings Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
125.9m CNY

Based on the financial report for Dec 31, 2023, Connect Biopharma Holdings Ltd's Total Liabilities & Equity amounts to 125.9m CNY.

What is Connect Biopharma Holdings Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-23%

Over the last year, the Total Liabilities & Equity growth was -90%. The average annual Total Liabilities & Equity growth rates for Connect Biopharma Holdings Ltd have been -51% over the past three years , -23% over the past five years .

Back to Top